SCHEMBL4630708

SCHEMBL4630708

Cc1nc(I)cn1-c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.46
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
NR3C1 P04150 1/20 0.38
NR3C2 P08235 1/20 0.38
PTGS2 P35354 4/20 0.38
PTGS1 P23219 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.36
POLB P06746 1/20 0.35
KCNH2 Q12809 1/20 0.34
ABCB1 P08183 1/20 0.34
MCHR1 Q99705 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2379274 0.81 GRM5 (0.35) GRM5NR3C1NR3C2
SCHEMBL2378788 0.81 GRM5 (0.43) GRM5GABRA2GABRB2HPGD
SCHEMBL2172521 0.77 KCNH2 (0.38) GRM5GABRA2GABRB2PTGS2PTGS1
SCHEMBL25384433 0.75 PTGS2 (0.39) GABRA2GABRB2NR3C1PTGS2PTGS1
SCHEMBL2171789 0.74 GRM5 (0.43) GRM5GABRA2GABRB2NR3C1NR3C2
SCHEMBL2173893 0.74 GRM5 (0.56) GRM5GABRA2GABRB2NR3C1NR3C2
SCHEMBL2175491 0.74 PTGS2 (0.43) GRM5GABRA2GABRB2NR3C1NR3C2
SCHEMBL2172650 0.73 POLB (0.42) MEN1KMT2APOLB
SCHEMBL4629721 0.73 MCHR1 (0.38) PTGS2PTGS1HPGDKCNH2MCHR1
SCHEMBL10460756 0.73 KDM4E (0.43) MEN1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606277-B8 IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-10-15 EP disclosed
EP-1606277-B1 IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-05-14 EP disclosed
US-7153874-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-12-26 US disclosed
EP-1606277-A1 IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-12-21 EP disclosed
US-20040229917-A1 Imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-11-18 US disclosed
WO-2004080998-A1 IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229917-A1 Imidazole derivatives GRIK4, GRIA4, GRIK5 GRM5 10/4885GABRA2 137/4885GABRB2 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.